Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 16;6(8):e1338236. doi: 10.1080/2162402X.2017.1338236

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 4. — Initial LTX-315 treatment elicits long-term tumor protection. (A) Time schedule of experiment to study long-term effects of LTX-315 therapy. Rats were s.c. inoculated with 1·10⁵ rTMSCs in the upper flank. At day 6, rats in the treatment group (n = 8) received an i.t. injection of 1 mg LTX-315 daily for 7 consecutive days. Rats in the control group (n = 6) remained untreated, and were killed after gross tumor development. The LTX-315 treated rats were considered cured and housed for 60 weeks before s.c. and i.p. rechallenge with 2 × 10⁴ rTMSCs. Other control rats (n = 6 for each tumor site) were included. Representative luminescence images after (B) s.c. and (D) i.p. tumor rechallenge, total photon flux is summarized (mean ± SD) and depicted (C, E).